Elaine Chen , 2025-08-19 13:52:00
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Today we look at what some people in the industry are calling a “pharm to table” trend. Read on to learn more about it.
Viking oral obesity pill study results disappoint
From my colleague Allison DeAngelis: A new oral weight loss drug developed by Viking Therapeutics hit the mark in a mid-stage clinical trial, but the side effect and discontinuation rates have disappointed investors.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.